Global Hypogonadism Drug Market Growth 2025-2031
Description
The global Hypogonadism Drug market size is predicted to grow from US$ 3847 million in 2025 to US$ 5335 million in 2031; it is expected to grow at a CAGR of 5.6% from 2025 to 2031.
There are two drugs for treatment of hypogonadism, one is testosterone replacement therapy drug; The other is used for gonadotropin treatment, which aims to maintain the normal development of male secondary sexual characteristics and restore fertility.
Rising population and rising incidence and prevalence of chronic diseases such as diabetes and obesity drive the market growth. According to clinical studies, the testosterone levels of men aged 60-80 are 20% and 80% lower than those of young men, respectively. Hypogonadism is most common in men over the age of 60. In countries such as Japan, China, and the U.S., the demand for male hypogonadism treatment has surged due to rising geriatric population and surging infertility rates.
LP Information, Inc. (LPI) ' newest research report, the “Hypogonadism Drug Industry Forecast” looks at past sales and reviews total world Hypogonadism Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Hypogonadism Drug sales for 2025 through 2031. With Hypogonadism Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hypogonadism Drug industry.
This Insight Report provides a comprehensive analysis of the global Hypogonadism Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hypogonadism Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hypogonadism Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hypogonadism Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hypogonadism Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Hypogonadism Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection
Capsule
Segmentation by Application:
Hospital
Pharmacy
Specialist Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Allergan
AbbVie
Endo Pharmaceuticals
Pfizer Inc.
Clarus Therapeutics, Inc.
Aytu BioScience, Inc.
Antares Pharma
Upsher-Smith Laboratories, Inc.
Beijing Shuanghe Pharmaceutical Co., Ltd
Tianjin Jinyao Amino Acid Co., Ltd
Shanghai General Pharmaceutical Co., Ltd
Tianjin Lisheng Pharmaceutical Co., Ltd
Chengde Jiulong Pharmaceutical Co., Ltd
Harbin Pharmaceutical Group
Shenyang Keda Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hypogonadism Drug market?
What factors are driving Hypogonadism Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hypogonadism Drug market opportunities vary by end market size?
How does Hypogonadism Drug break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
There are two drugs for treatment of hypogonadism, one is testosterone replacement therapy drug; The other is used for gonadotropin treatment, which aims to maintain the normal development of male secondary sexual characteristics and restore fertility.
Rising population and rising incidence and prevalence of chronic diseases such as diabetes and obesity drive the market growth. According to clinical studies, the testosterone levels of men aged 60-80 are 20% and 80% lower than those of young men, respectively. Hypogonadism is most common in men over the age of 60. In countries such as Japan, China, and the U.S., the demand for male hypogonadism treatment has surged due to rising geriatric population and surging infertility rates.
LP Information, Inc. (LPI) ' newest research report, the “Hypogonadism Drug Industry Forecast” looks at past sales and reviews total world Hypogonadism Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Hypogonadism Drug sales for 2025 through 2031. With Hypogonadism Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hypogonadism Drug industry.
This Insight Report provides a comprehensive analysis of the global Hypogonadism Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hypogonadism Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hypogonadism Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hypogonadism Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hypogonadism Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Hypogonadism Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection
Capsule
Segmentation by Application:
Hospital
Pharmacy
Specialist Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Allergan
AbbVie
Endo Pharmaceuticals
Pfizer Inc.
Clarus Therapeutics, Inc.
Aytu BioScience, Inc.
Antares Pharma
Upsher-Smith Laboratories, Inc.
Beijing Shuanghe Pharmaceutical Co., Ltd
Tianjin Jinyao Amino Acid Co., Ltd
Shanghai General Pharmaceutical Co., Ltd
Tianjin Lisheng Pharmaceutical Co., Ltd
Chengde Jiulong Pharmaceutical Co., Ltd
Harbin Pharmaceutical Group
Shenyang Keda Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hypogonadism Drug market?
What factors are driving Hypogonadism Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hypogonadism Drug market opportunities vary by end market size?
How does Hypogonadism Drug break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
131 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Hypogonadism Drug by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Hypogonadism Drug by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
